DOCSLIB.ORG

Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission Shire Pharmaceuticals Group plc Annual review and summary financial statement 2003 Shire: a focused global pharmaceutical company Focusing on a bright future Shire Pharmaceuticals Group plc The Shire mission Our mission is to become the leading company in meeting the needs of the specialist physician. We want to achieve this by developing and Contents 01 Financial highlights marketing products of the highest quality 02 Chairman’s statement 04 Chief Executive Officer’s review for the treatment of serious diseases, 06 Product portfolio 07 Product development pipeline which are treated by medical specialists. 08 Operating review 22 CSR: Corporate and social responsibility 24 Financial review We aim to provide high quality and effective 28 Board of Directors 30 The Executive Committee products that enhance the health and 32 Directors’ remuneration report 44 Corporate governance quality of life of people around the world statement Financial Statements and contribute to the long-term business 48 Statement of Directors’ responsibilities – Report of success of our Company, to the benefit independent auditors 49 Consolidated balance sheets 50 Consolidated statement of all our stakeholders. of operations 51 Consolidated statements of changes in shareholders’ equity We are driven by the needs of all our 52 Consolidated statements of cash flows stakeholders: patients, their families and 53 Notes to the consolidated financial statements 87 Five-year review caregivers, doctors and medical specialists, 88 Summary financial statement 93 Notes to summary employees and partner companies, the financial statement community in which we live and work and, Other 94 Shire head office and main operating locations of course, our shareholders. 95 Shareholder information 96 Trade marks – Cautionary statements We also want to be the employer of choice in our sector, attracting and retaining highly skilled and talented people, who play an active part in the development of our Company, by rewarding excellence and recognising individual contributions. Shire Pharmaceuticals Group plc Financial highlights 01 Financial results 2003: Shire revenues continued to grow – exceeding US$1.2 billion Revenue growth $m 2003: 1,237.1 2002: 1,037.3 +19% Revenue $m R&D spend $m Operating income $m 2003: 1,237.1 2003: 215.8 2003: 394.6 2002: 1,037.3 +19% 2002: 189.2 +14% 2002: 327.0 +21% 03 03 03 02 02 02 Diluted EPS Diluted EPS: ADS Revenue growth over last ordinary shares five years 2003: 54.2 cents 2003: 162.6 cents 2002: 49.0 cents +11% 2002: 147.1 cents +11% 03 $1,237.1m 02 $1,037.3m 01 $853.0m 03 03 00 $647.7m 02 02 99 $515.4m Sources of Sources of Revenue by reporting revenue % revenue $m segment % 8 8 4 3 1 1 7 7 2 6 6 5 5 4 4 1 3 2 3 2 1. ADDERALL/ADDERALL XR 43 1. ADDERALL/ADDERALL XR 535.6 1. US 69 2. AGRYLIN 11 2. AGRYLIN 132.5 2. International 14 3. PENTASA 8 3. PENTASA 99.3 3. Biologics 2 4. CARBATROL 4 4. CARBATROL 52.4 4. Corporate 15 5. PROAMATINE 4 5. PROAMATINE 49.3 6. CALCICHEW 2 6. CALCICHEW 28.9 7. OTHERS 11 7. OTHERS 135.5 8. ROYALTIES 17 8. ROYALTIES 203.6 02 Shire Pharmaceuticals Group plc Chairman’s statement We have achieved clear success to date and through greater focus expect more to follow through 2004 and beyond The international pharmaceutical industry has 2003 results changed considerably during the last decade In 2003, Shire once again produced strong and this continued in 2003. Our view at Shire financial results. Income from continuing is that, whatever their size, successful operations, before income taxes and equity pharmaceutical companies now require focus, method investees, increased 17% to US$384.5 particularly in their product markets, customer million. Revenues were up 19% to US$1,237.1 base, research and development and cost control. million. Diluted earnings per ordinary share Unsurprisingly, these are areas that we focused was 54.2 cents. on in 2003 and will continue to do so in the current year. We have achieved clear success Significantly, Shire’s cash position remained strong to date and through greater focus expect more with net cash of US$1,036 million, an increase to follow in 2004 and beyond. of US$230 million on 2002, which will be used for future expansion. Within his short time as Chief Executive Officer, Matthew Emmens has shaped Shire for its The Board future. Our newly deployed strategic model We continue to develop the Shire Board to is designed to optimise the opportunities for match the demands of what is now a large, us and deal with future challenges within the international business in a changing industry. Shire will position itself as the leading pharmaceutical marketplace. company in meeting the needs of the specialist physician with a focus on fewer, later stage and In line with newly published regulations on lower risk projects. This means that we don’t corporate governance, Shire has talked to a invent products but acquire them. Therefore we range of shareholders and taken advice on how are focusing on not only the type of deals that to best meet these guidelines. A programme of give us a good pipeline, but how to best develop implementation is underway and more detail can Dr James Cavanaugh them with ultimate market success in mind. be found in the corporate governance statement Chairman We will continue to enhance our positions in of this document on page 44. the key areas of Central Nervous System (CNS), Gastrointestinal (GI) and renal medicine, while In March 2003, Matthew Emmens was appointed remaining alert for new therapeutic areas that as Chief Executive Officer. He has a strong would benefit from our expertise. track record of success over an international pharmaceutical career spanning nearly 30 years. Shire’s sales force continues to deliver impressive Matthew was a founder of the joint venture Astra results and its reputation amongst specialist Merck Inc. in the US, and later its President and physicians makes it a partner of choice when Chief Executive. Before joining Shire, he was it comes to potential acquisitions and in-licensing President of the global pharmaceutical business projects and products. Our strong cash position of Merck KGaA in Germany. gives us considerable flexibility in looking at potential mergers and acquisitions (M&A) opportunities and we have identified a small number of highly attractive targets. Shire Pharmaceuticals Group plc Chairman’s statement 03 We are confident of delivering sustained growth in 2004 and beyond, following the momentum we developed in 2003 In July 2003, Shire’s Board appointed Robin People Buchanan as a new non-executive Director. Shire had 1,815 employees worldwide as He is a member of the Company’s Remuneration of 31 December 2003. We believe strongly Committee. Robin is the Senior Partner of the in the importance of hiring well-qualified, London office of business consultants Bain experienced staff with proven records of success. & Company and a member of the firm’s The Group’s future progress depends upon worldwide management committee. Since joining its ability to attract and retain such individuals. Bain & Company in 1982, he has been involved Shire will continue to apply and develop a strong in strategy development and organisation advice focus on staff recruitment and development for Bain’s clients in most industry sectors, at all levels. including healthcare. Current trading and future prospects On 10 March 2004, we announced that The Company is trading in line with our David Kappler will join the Shire Board as expectations. Shire has well-established positions a non-executive Director in April and will take in growing markets, a well defined strategy, strong over the Chairmanship of the Audit Committee cash resources and a promising pipeline of late in July 2004. David recently retired as Chief stage drugs. Consequently, we are confident Financial Officer of Cadbury Schweppes plc, of delivering sustained growth in 2004, following the FTSE and NYSE listed global confectionery the momentum we developed in 2003. and beverages group, where he held a range of senior finance positions during his almost 40-year career with the group. While welcoming Matthew, Robin and David, I would also like to thank Francesco Bellini and Gérard Veilleux for the contribution they have made to the Board, having completed their two-year contracts with Shire. 04 Shire Pharmaceuticals Group plc Chief Executive Officer’s review Our opportunities lie in addressing underserved markets and growing products beyond what the consensus of opinion might be In 2003, Shire once again delivered a very Our model emphasises the ‘D’ in R&D. Therefore, strong financial performance. During the summer, our ‘R’ is based on finding products invented we began implementing a new strategy aimed by others. I believe this is a sound idea because at ensuring continued future growth. Since its ‘in house’ R&D has not met the needs of the inception, Shire has grown through acquisitions, larger companies. During 2003, slightly less than subsequent product development and effective one-half of all products marketed by large marketing. This idea remains the foundation pharmaceutical companies were not invented of our model. Some could say that it is ‘back there. This percentage has increased steadily to the future’ in that we will search (take the ‘re’ over the last decade. Conversely, approximately from research), and then develop and market. 70% of all Phase III* projects were developed But at this point in our history, this would be by non-major pharmaceutical companies. over-simplification. The Group has migrated from Our conclusion is that pre-clinical research this simple idea, and making this proven concept is becoming less predictable and the creativity viable in today’s larger organisation has kept may lie in a diffuse cross-section of smaller us very busy.
Load more

Recommended publications
  • The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019
    The Scientific Organizing Committee gratefully acknowledges the pharmaceutical and biotechnology industry for their generous support of WCBP 2019: Strategic Diamond Program Partners F. Hoffmann-La Roche Ltd. Genentech, a Member of the Roche Group Strategic Platinum Program Partners Amgen Inc. Biogen MedImmune, A member of the AstraZeneca Group Strategic Gold Program Partners Eli Lilly and Company Merck & Co., Inc. Novo Nordisk A/S Pfizer, Inc. Strategic Silver Program Partner Sanofi 1 Gold Program Partner Bill and Melinda Gates Foundation Silver Program Partners BioMarin Pharmaceutical Inc. Bristol-Myers Squibb Company GlaxoSmithKline Jazz Pharmaceuticals Bronze Program Partner Seattle Genetics, Inc. Friend of CASSS Janssen R&D, LLC 2 The Scientific Organizing Committee gratefully acknowledges the Program Partners and Exhibitors for their generous support of WCBP 2019: Diamond Program Partners Agilent Technologies Catalent Pharma Solutions Eurofins Pharma Discovery Services ProteinSimple, a Bio-Techne brand Thermo Fisher Scientific Waters Corporation Platinum Program Partners BioAnalytix SCIEX Bronze Program Partner Bruker Corporation 3 The Scientific Organizing Committee gratefully acknowledges the Exhibitors for their generous support of WCBP 2019: Exhibitor Partners 908 Devices Inc. NanoImaging Services Agilent Technologies New England Biolabs Associates of Cape Cod, Inc. Postnova Analytics Inc. BioAnalytix Inc. Pressure BioSciences Inc. Bruker Corporation Protein Metrics, Inc. Catalent Pharma Solutions ProteinSimple, a Bio-Techne brand Charles River Laboratories ProZyme, A part of Agilent Covance, Inc. RedShift BioAnalytics, Inc. Cygnus Technologies Rockland Immunochemicals, Inc. Envigo SCIEX Eurofins BioPharma Product Testing SGS Life Science Services Eurofins Pharma Discovery Services Shimadzu Scientific Instruments, Inc. FortéBio - Biologics by Molecular Devices Thermo Fisher Scientific GE Healthcare Life Sciences U.S.
    [Show full text]
  • VOLUME II Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018
    Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018 VOLUME II Temple University Financial Disclosure Report Purchase of Goods and Services Contracts Notes and Definitions The following report provides the required disclosures for reporting the purchase of goods and services contracts. The University’s Banner Finance System does not include data enabling the distinction between the purchases of goods and services. Therefore, a single report is provided that includes both. Expenditures are categorized in the attached report using the following categories: General Supplies & Services: o General supplies, expendable equipment and software. Health Service Programs: o Animal lab, professional billing and other outside professional services. Insurance: o Malpractice, property, general liability, and employees insurances. Interest & Taxes: o Bond interest, real estate tax and debt service costs. Library: o Books, electronic periodicals, subscriptions and film. Professional Fees & Contracts: o Auditing, legal and collection fees and subcontracts. Property, Plant & Equipment: o Capital equipment, buildings and building improvements. Rent: o Equipment, building and office rentals. Repairs & Maintenance: o Equipment repair, maintenance of buildings and grounds. Telecommunications: o Telephone equipment, data communications and cellular services. Travel: o Travel agency fees, foreign and domestic travel expenses. Utilities: o Electric, gas, water, sewer, steam, chilled water and other miscellaneous utilities expenses. Each entry provides the category into which the purchase falls, the vendor name and address and the amount of the purchase. There is no more than one entry per vendor for a single category within a responsibility center. Purchases of goods and services in the Disclosure Report include those which equal or exceed $1,000 for each vendor from all Budgeted Operating Funds including Temple University Physicians.
    [Show full text]
  • Economic Development Strategy and Implemenation
    MEDIA ECONOMIC DEVELOPMENT STRATEGY AND IMPLEMENTATION PLAN October 31, 2017 REPORT SUBMITTED TO: Jeff Smith, Borough Manager Media Borough 301 N. Jackson Street Media, PA 19063 REPORT SUBMITTED BY: Econsult Solutions, Inc. 1435 Walnut Street, 4th Floor Philadelphia, PA 19102 Econsult Solutions, Inc.| 1435 Walnut Street, 4th floor| Philadelphia, PA 19102 | 215-717-2777 | econsultsolutions.com Media, Pennsylvania | Economic Development Strategy and Implementation Plan | i TABLE OF CONTENTS 1.0 Introduction ............................................................................................................................ 1 1.1 Our Charge and Our Approach ................................................................................ 1 1.2 Overview of the Report ............................................................................................... 2 2.0 Economic Vision and Goals ................................................................................................. 4 2.1 Vision Overview ............................................................................................................ 4 2.2 Public Outreach Methodology .................................................................................. 4 2.3 Summary of Public Outreach Findings ...................................................................... 4 2.4 Principles for the Economic Development Vision and Goals ................................ 5 2.5 Vision Statement .........................................................................................................
    [Show full text]
  • Introducing the IMED Biotech Unit What Science Can Do Introduction What Science Can Do
    Introducing the IMED Biotech Unit What science can do Introduction What science can do At AstraZeneca, our purpose is to push the Our IMED Biotech Unit applies its research and Our approach to R&D development capabilities and technologies to The IMED Biotech Unit plays a critical boundaries of science to deliver life-changing accelerate the progress of our pipeline. Through role in driving AstraZeneca’s success. Working together with MedImmune, medicines. We achieve this by placing science great collaboration across our three science units, our global biologics arm and Global we are confident that we can deliver the next wave Medicines Development (GMD), our at the centre of everything we do. late-stage development organisation, of innovative medicines to transform the lives of we are ensuring we deliver an innovative patients around the world. and sustainable pipeline. Pancreatic beta cells at different Eosinophil prior to Minute pieces of circulating tumour DNA stages of regeneration apoptosis (ctDNA) in the bloodstream IMED Biotech Unit MedImmune Global Medicines Development Focuses on driving scientific advances Focuses on biologics research and Focuses on late-stage development in small molecules, oligonucleotides and development in therapeutic proteins, of our innovative pipeline, transforming other emerging platforms to push the monoclonal antibodies and other next- exciting science into valued new boundaries of medical science. generation molecules to attack a range medicines and ensuring patients of diseases. around the world can access them. It’s science that compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.
    [Show full text]
  • The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
    The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry By: Maitri Punjabi Honors Thesis Economics Department The University of North Carolina at Chapel Hill March 2016 Approved: ______________________________ Dr. Jonathan Williams Punjabi 2 Abstract This paper analyzes the effect of the changing nature of innovation on pharmaceutical firm market value from the years 1987 to 2010 by using U.S. patent and claim data. Over the years, firms have started shifting focus from primary innovation to secondary innovation as new ideas and new compounds become more difficult to generate. In this study, we analyze the impact of this patent portfolio shift on the market capitalization of pharmaceutical firms. After using firm fixed effects and the instrumental variable approach, we find that there exists a strong positive relationship between secondary innovations and the market value of the firm– in fact, we find a stronger relationship than is observed between primary innovation and market value. When focusing on the different levels of innovation within the industry, we find that this relationship is stronger for less-innovative firms (those that have produced fewer patents) than it is for highly- innovative firms. We also find that this relationship is stronger for firms that spend less on research and development, complementing earlier findings that research productivity is declining over time. Punjabi 3 Acknowledgements I would primarily like to thank my adviser, Dr. Jonathan Williams, for his patience and constant support. Without his kind and helpful attitude, this project would have been a much more frustrating process. Through his knowledge of the industry, I have gained valuable insight and have learned a great deal about a unique and growing field.
    [Show full text]
  • Creating Stakeholder Value Creating Stakeholder Value
    8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:27 Page FC1 Shire plc Annual ReportShire 2011 Shire plc Annual Report 2011 Creating stakeholder value Creating stakeholder value Effective treatments and services Commitment to superior treatments Improved public for their patients health and societal value Better lives for patients Superior clinical Brave culture driving evidence and clear innovation to deliver economic benefits value to all Return to enable further investment shire.com 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:27 Page IFC1 Shire plc Annual Repo Shire trademarks The following are trademarks either owned or licensed by Shire plc or companies within the Shire Group (the “Group” or the “Company”) which are the subject of trademark registrations in certain territories, or which are owned by third parties as indicated and referred to in this Annual Report: ADDERALL XR® (mixed salts of a single entity amphetamine) AGRYLIN® (anagrelide hydrochloride) APLIGRAF® (trademark of Organogenesis, Inc. (“Organogenesis”)) APRISO® (trademark of Salix Pharmaceuticals, Ltd. (“Salix”)) ASACOL® (trademark of Medeva Pharma Suisse AG (used under license by Warner Chilcott Company, LLC (“Warner Chilcott”))) ATRIPLA® (trademark of Bristol Myers Squibb Company (“BMS”) and Gilead Sciences, Inc. (“Gilead”)) BERINERT P® (trademark of Aventis Behring GmbH) ® CALCICHEW range (calcium carbonate with or without vitamin D3) CARBATROL® (carbamazepine extended release capsules) CEREZYME® (trademark of Genzyme Corporation (“Genzyme”))
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • For the PLUS
    BUCKS UNITEDANNUAL REPORT united wAy Of bucks county& MAGAZINE Multiplier AwARDS pageS 12-15 BUCKS KNOCKS OUT HUNGER pageS 32-35 CAMPAIGN fOR THE GREATER GOOD pageS 46-49 Local Perspectives on Education, Income & Health, 14 Reasons to Explore PLUS Bucks County, A Local Recipe for Every Season, By the Numbers, and more! United Way of Bucks County Comcast congratulates United Way of Bucks County awards recipients, past and present, including: Brian Jeter Dr. Stanton Kelton Service Award Nan Mauro Paul Sauerbry Award tABLe oF contents 20 36 46 what's cooking? Leading the way Achieving corporate try a recipe for each season from some A local couple's legacy of caring for Philanthropic goals of our favorite local farms. Bucks county. the simple way to bring your team together for the greater good. AnnuAl RepoRt Businesses giving BAck 41 INCOME: Early Investing: 3 Letter from CEO Jamie Haddon 27 GE: Where Giving Back Matters Simple Ways to Teach Our Children about Saving & Investing 5 Letter from CFO John Ramirez 28 Comcast: A Long History of Living United 43 HEALTH: Kicking Off Community 6 Board of Directors & Introduction Health Collaboration of New Board Members 29 National Penn Bank: Sharing Time & Treasure in Local Communities 44 Shaping the Futures of Girls in 7 An Agency with Impact Bucks County Through 8 Kelton Award Winner: Brian Jeter 31 Hill Wallack LLP: Regional Mind, Body & Spirit Strength, Local Impact 10 Sauerbry Award Winner: 46 UW Bucks Campaigns Help You Nan Mauro locAl peRspectives Achieve Corporate Philanthropic Goals 60
    [Show full text]
  • Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
    Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500 www.dyax.com Other Offices Dyax SA, Liege, Belgium ADVANCING NOVEL THERAPEUTIC PRODUCTS Dyax Corp. Annual Report 2003 Corporate Information Dyax Achievements 2003 Dyax Goals 2004 Directors Executive Officers and Stock Listing Henry E. Blair Key Employees Common stock has been traded on the Nasdaq Stock Market Advances in Clinical Development Clinical Development Chairman, President and Henry E. Blair* under the symbol DYAX since our initial public offering in Milestones Chief Executive Officer, Chairman, President and August 14, 2000. DX-88/Hereditary Angioedema Dyax Corp. Chief Executive Officer DX-88/Hereditary Constantine E. Stephen S. Galliker, CPA* The following table gives the quarterly high and low sales G Completed 9-patient Phase II trial, met primary endpoints Angioedema Anagnostopoulos, Ph.D. EVP Finance and prices of our common stock for the last three years. G Genzyme Corporation joined Dyax as joint venture partner Managing General Partner, Administration and G Complete Phase II 2001 2002 2003 G Gateway Associates, LP Chief Financial Officer Completed 3 of 4 dose cohorts in 48-patient Phase II EDEMA1 trial EDEMA1 study High Low High Low High Low G Susan B. Bayh, J.D. Lynn G. Baird, Ph.D.* Initiated Phase II EDEMA2 trial G Periodically observe James W. Fordyce SVP Development First Quarter $20.94 $6.56 $11.38 $3.10 $2.25 $1.52 G Orphan Drug designation granted in U.S. and Europe effects of repeat dosing in Phase II EDEMA2 Managing Partner, Robert C. Ladner, Ph.D. Second Quarter $19.99 $6.81 $ 4.68 $3.20 $4.90 $1.67 Fordyce & Gabrielson, LLC SVP and Chief DX-88/On-Pump Open Heart Surgery (CABG) study Third Quarter $21.24 $6.05 $ 4.20 $1.65 $7.50 $2.58 Mary Ann Gray, Ph.D.
    [Show full text]
  • Philly Tech Week 2021 Presented by Comcast Will Be Produced by PACT
    Philly Tech Week 2021 Presented by Comcast will be produced by PACT, in partnership with longtime organizer Technical.ly To be held May 7-15, 2021, the 11th annual will feature a unique collaboration between two of Philadelphia’s tech community anchors PHILADELPHIA (FEBRUARY 10, 2021) -- Today local tech economy news site Technical.ly and regional tech council Philadelphia Alliance for Capital and ​ ​ Technologies (PACT) announce their partnership to produce Philly Tech Week 2021 ​ ​ Presented by Comcast. ​ Since 2010, Technical.ly, which is published by digital media company Technically Media, has served as lead organizer for Philly Tech Week, an annual open calendar of events celebrating technology, entrepreneurship and innovation. The week has always featured a wide array of supportive collaborators and partners, including PACT. This will change for the 11th annual which will take place virtually May 7-15, 2021. A virtual town hall on PTW21 will be held on Monday, Feb. 22. Register here. ​ ​ The two organizations are trialing a partnership in which PACT will leverage its strengths and longstanding history as a convener of the regional tech and healthcare innovation community to serve as lead organizer, with Technical.ly taking a secondary role. PACT will lead community organizing efforts, including managing the week’s community calendar — which routinely includes more than 100 events — and centralize the week’s messaging. Technical.ly will produce its annual future of work conference Introduced and the Technical.ly Developers Conference. The Technical.ly newsroom will continue to track the Philadelphia tech economy, which celebrates innovation in Philadelphia annually with Philly Tech Week.
    [Show full text]
  • Astrazeneca Plc
    6/15/2020 AstraZeneca - Wikipedia AstraZeneca AstraZeneca plc[3] is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its global AstraZeneca plc headquarters in Cambridge, England.[4] Its R&D is concentrated in Cambridge, Gaithersburg, Maryland, and Mölndal in Sweden.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, Type Public limited neuroscience, respiratory and inflammation.[6] company Traded as LSE: AZN (https:// The company was founded in 1999 through the merger of the www.londonstocke [7][8] Swedish Astra AB and the British Zeneca Group (itself formed xchange.com/exch by the demerger of the pharmaceutical operations of Imperial ange/searchengin Chemical Industries in 1993). Since the merger it has been among e/search.html?lang the world's largest pharmaceutical companies and has made =en&x=0&y=0&q= numerous corporate acquisitions, including Cambridge Antibody AZN) Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) NYSE: AZN (http and Definiens (by MedImmune in 2014). s://www.nyse.com/ quote/XNYS:AZN) AstraZeneca has a primary listing on the London Stock Exchange Nasdaq and is a constituent of the FTSE 100 Index. It has secondary listings Stockholm: AZN (ht on the New York Stock Exchange and the OMX exchange. tp://www.nasdaqom xnordic.com/aktier/ microsite?language Contents Id=1&Instrument=S SE3524) History FTSE 100 2000–06 Component 2007–12: The patent cliff and subsequent acquisitions ISIN GB0009895292 2013
    [Show full text]
  • Pharmaceuticals in the Environment
    Pharmaceuticals in the Environment As a responsible healthcare company, we are committed to the health and safety of our society and planet. We make it a priority to effectively manage the risks associated with pharmaceuticals in the environment (PIE). 1 How do Pharmaceutical Products get into the Environment? Pharmaceuticals enter the environmental mainly as AstraZeneca supports actions based on scientific a result of patient use, where they can pass through evidence to address the challenges presented by PIE. our bodies and into waterways. Drug manufacture and These include: the improper disposal of unused medicines also add • Assessing the environmental risk of our medicines to the trace levels of pharmaceuticals in rivers, lakes, to support drug marketing authorisations soils, and, sometimes, drinking water. AstraZeneca recognises that, even in such low concentrations, • Actively managing the environmental risks resulting the risks associated with Pharmaceuticals in the from our manufacturing Environment (PIE) should be determined, minimised • Supporting industry and government efforts to and managed. improve medicine disposal programs and education • Co-sponsoring research to fill scientific gaps 88% to understand and mitigate the risks of PIE. as a result of patient use To learn more about the risks associated with PIE and what we are doing to manage them please click here. 2% attributed to waste Pharmaceuticals from production in the environment 10% from unused medicines that people don’t dispose of properly 2 Societal Concerns about PIE Trace amounts of pharmaceuticals have been detected in the environment for more than 20 years. As environmental monitoring expands and the methods for measuring pharmaceuticals in the environment become more sophisticated and detection limits get better, the geographical scope and number of pharmaceuticals measured in the environment will grow.
    [Show full text]